BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38457199)

  • 21. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.
    Ayoubian H; Ludwig N; Fehlmann T; Menegatti J; Gröger L; Anastasiadou E; Trivedi P; Keller A; Meese E; Grässer FA
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and Epstein-Barr encoding region status in lymphomas: A retrospective multicenter study in Huaihai Lymphoma Working Group.
    Shen Z; Hu L; Yao M; He C; Liu Q; Wang F; Gu W; Wang Y; Dong M; Zhu T; Yin T; Li F; Jin Y; Huang S; Zhang H; Sang W;
    Int J Cancer; 2022 Jan; 150(2):327-334. PubMed ID: 34520566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorder.
    Daroontum T; Kohno K; Inaguma Y; Okamoto A; Okamoto M; Kimura Y; Nagahama M; Sakakibara A; Satou A; Nakamura S
    Pathol Int; 2019 Jan; 69(1):37-41. PubMed ID: 30450620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors.
    Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus-negative diffuse large B-cell lymphoma hosts intra- and peritumoral B-cells with activated Epstein-Barr virus.
    Stuhlmann-Laeisz C; Szczepanowski M; Borchert A; Brüggemann M; Klapper W
    Virchows Arch; 2015 Jan; 466(1):85-92. PubMed ID: 25339301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
    Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
    Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological analysis of neoplastic PD-L1-positive EBV
    Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus (EBV) provides survival factors to EBV
    Wu L; Ehlin-Henriksson B; Zhou X; Zhu H; Ernberg I; Kis LL; Klein G
    Immunology; 2017 Dec; 152(4):562-573. PubMed ID: 28699226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified.
    Hoffmann JC; Chisholm KM; Cherry A; Chen J; Arber DA; Natkunam Y; Warnke RA; Ohgami RS
    Hum Pathol; 2016 Feb; 48():9-17. PubMed ID: 26772393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. pSTAT3 and MYC in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Teoh SH; Khoo JJ; Abdul Salam DSD; Peh SC; Cheah SC
    Malays J Pathol; 2019 Dec; 41(3):273-281. PubMed ID: 31901912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
    Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
    PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
    Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
    Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
    Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
    Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.
    Kawano T; Tsuyuki Y; Suzuki Y; Shimada K; Kato S; Takahara T; Mori M; Nakaguro M; Sakakibara A; Nakamura S; Satou A
    Am J Surg Pathol; 2021 Dec; 45(12):1606-1615. PubMed ID: 34534136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
    Wang E; Papavassiliou P; Sebastian S
    Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time.
    Chang ST; Lu YH; Lu CL; Weng SF; Lin SH; Kuo SY; Chuang YT; Takeuchi K; Ohshima K; Chuang SS
    J Clin Pathol; 2014 Apr; 67(4):326-32. PubMed ID: 24218026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population.
    Hofscheier A; Ponciano A; Bonzheim I; Adam P; Lome-Maldonado C; Vela T; Cortes E; Ortiz-Hidalgo C; Fend F; Quintanilla-Martinez L
    Mod Pathol; 2011 Aug; 24(8):1046-54. PubMed ID: 21499229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.